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A variety of molecules in human blood have
been implicated in the inhibition of HIV-1. How-
ever, it remained elusive which circulating natu-
ral compounds are most effective in controlling
viral replication in vivo. To identify natural HIV-1
inhibitors we screened a comprehensive pep-
tide library generated from human hemofiltrate.
The most potent fraction contained a 20-resi-
due peptide, designated VIRUS-INHIBITORY
PEPTIDE (VIRIP), corresponding to the C-prox-
imal region of a1-antitrypsin, the most abun-
dant circulating serine protease inhibitor.
We found that VIRIP inhibits a wide variety of
HIV-1 strains including those resistant to
current antiretroviral drugs. Further analysis
demonstrated that VIRIP blocks HIV-1 entry
by interacting with the gp41 fusion peptide
and showed that a few amino acid changes
increase its antiretroviral potency by two orders
of magnitude. Thus, as a highly specific natural
inhibitor of the HIV-1 gp41 fusion peptide, VIRIP
may lead to the development of another class of
antiretroviral drugs.
INTRODUCTION
A variety of components in human blood and tissues have
been implicated in the inhibition of HIV-1 replication in in-fected individuals. For example, the discovery that che-
mokines bind to cofactors of HIV-1 entry and block viral
replication represented a major breakthrough in AIDS
research and led to the development of several novel
types of antiretrovirals targeting various steps in the viral
entry process (reviewed in Moore and Stevenson, 2000;
Ray and Doms, 2006). However, it was frequently proven
difficult to purify and characterize the antiviral com-
pound(s) released from human cells or tissues. For exam-
ple, it seems that the antiviral factor released by CD8+ T
cells, initially described 20 years ago (Walker et al.,
1986), has not yet been identified, although a variety of
natural anti-HIV factors has since been detected in the
long and intensive search (reviewed in Levy, 2003). Major
obstacles in identifying antiviral factors circulating in the
human body in a systematic, effective, and unbiased man-
ner are the limited quantities of available human material
and the lack of standardized methods to purify biologically
active natural HIV inhibitors.
Progress in the generation and analysis of peptide li-
braries derived from human body fluids or tissues allowed
these limitations to be overcome. For example, technolo-
gies have been developed for separating peptides from
large amounts of up to 10,000 liter hemofiltrate (HF), which
is available in abundance from patients with chronic renal
failure (Forssmann et al., 1992; Schulz-Knappe et al.,
1996). HF-derived peptide libraries contain an estimated
number of more than one million different peptides and
small proteins, representing essentially all circulating
compounds with a molecular weight below 30 kDa. These
include chemokines, defensins, cytokines, and hormones,
in a highly concentrated and bioactive form (Schulz-
Knappe et al., 1997). Previous studies demonstratedCell 129, 263–275, April 20, 2007 ª2007 Elsevier Inc. 263
Figure 1. Purification of VIRIP from Human Hemofiltrate
(A) Hemofiltrate pH pool 1 was subjected to RP-HPLC and the resulting fractions were assayed for antiviral activity. The red area specifies the active
fraction. The inlet shows inhibition of HIV-1 replication by fraction P1-20 (indicated by the arrows). Human PBMCs were infected with HIV-1 NL4-3 in
the presence of peptide fractions obtained from pH pool 1. Viral replication was measured by RT assay with cell-free culture supernatant obtained at
9 days post-infection. The results of two infections are shown (Exp. 1 and 2). The symbols specify wells with uninfected cells () or without peptide
added (+) in the two control (C) columns.
(B) MALDI-TOF analysis of the inhibitory fraction obtained at the last purification step revealed a major compound with a molecular mass of 2303
Dalton. Identification of the 20 aa sequence was conducted by Edman degradation.that such peptide libraries represent a useful source for
identification and purification of new natural anti-HIV-1
agents (Detheux et al., 2000; Mu¨nch et al., 2002). Notably,
the relative concentrations of the compounds correspond
to those of human plasma (Schulz-Knappe et al., 1996).
Thus, these libraries should allow identification of those
small circulating agents that are most relevant for control-
ling viral infection in vivo, at least in the absence of a spe-
cific antiviral host immune response.
Here, we performed a systematic screening of an
HF-derived peptide library for novel HIV inhibitors. We
identified a natural 20-residue C-proximal subfragment
of a1-antitrypsin (a1-AT), designated VIRUS-INHIBITORY
PEPTIDE (VIRIP), as a broad-based inhibitor of HIV-1.
Moreover, we found that a few amino acid changes en-
hanced antiretroviral potency of VIRIP by two orders of
magnitude. Functional and structural analyses revealed
that VIRIP inhibits HIV-1 entry by specific binding to the
gp41 fusion peptide (FP). In agreement with this distinct
inhibitory mechanism VIRIP and its derivatives remained
fully active even against HIV-1 strains resistant to currently
available antiretroviral drugs including fusion inhibitors.
Our data support the possibility that VIRIP may contribute
to controlling HIV-1 replication in infected individuals and
that derivates thereof are highly suitable for development
of a new class of HIV-1 inhibitors targeting the highly
conserved gp41 FP.
RESULTS
Isolation of an HIV-1 Inhibitor
from Human Hemofiltrate
A peptide library was established by enrichment and sep-
aration of peptides from human HF using cation exchange264 Cell 129, 263–275, April 20, 2007 ª2007 Elsevier Inc.and reversed phase (RP) chromatography (Schulz-
Knappe et al., 1997). A total of 322 different peptide-con-
taining RP-HPLC fractions from the HF peptide library
were screened to identify factors that block wild-type
HIV-1 NL4-3 (NL4-3wt) replication in human PBMCs.
One fraction (No. P1-20) was selected for detailed analysis
because it was not cytotoxic and displayed potent anti-
HIV-1 activity, indicated by the lack of detectable reverse
transcriptase (RT) activity in the culture supernatant (Fig-
ure 1A). The active peak was further purified by two addi-
tional chromatographic steps. MALDI-TOF analysis of the
inhibitory fraction obtained after the final step revealed
a major peak with a molecular mass of 2303 Da (Figure 1B).
Edman degradation identified the sequence LEAIPMSIP-
PEVKFNKPFVF showing that this peptide, VIRIP, corre-
sponds exactly to residues 353–372 of human a1-AT
(accession number P01009), the most abundant circulat-
ing serine protease inhibitor (Travis and Salvesen, 1983).
The a1-AT is produced mainly by the liver and controls
proteinases in many biological pathways even though its
main function is to protect the lung against proteolytic
damage from neutrophil elastase (Stoller and Abous-
souan, 2005).
VIRIP Inhibits HIV-1 Infection and Transmission
To exclude the possibility that a contaminating agent
might be responsible for the observed effects, we next
tested chemically synthesized VIRIP for antiviral activity.
The synthetic peptide inhibited infection of PBMC by X4-
and R5-tropic HIV-1 with a mean 50% inhibitory concen-
tration (IC50) of about 20 mM but had no effect on infection
by viral particles pseudotyped with vesicular stomatitis
virus (VSV-G) or murine leukemia virus (MLV) Env glyco-
proteins (Figure 2A). Importantly, VIRIP was not cytotoxic
Figure 2. Synthetic VIRIP Inhibits HIV-1 Replication and Transmission
(A) PBMCs were infected with X4-tropic NL4-3wt and R5-tropic V3 recombinants (blue) or with HIV-1 particles carrying heterologous VSV-G or MLV
Env proteins (green) all containing the luciferase reporter gene instead of nef in the presence of the indicated concentrations of VIRIP. Results shown in
all panels were confirmed in two to five independent experiments.
(B) Prestimulated PBMCs were infected with HIV-1 NL4-3 in the absence or presence of an inhibitor. Supernatants were harvested at regular intervals
and analyzed for RT activity. PSL, photo-stimulated luminescence.
(C) DCs were exposed to equal amounts of HIV-1 NL4-3 encoding the luciferase gene, washed, and cocultivated with autologous primary CD4+ T cells
in the presence of the indicated concentrations of VIRIP. As controls, DCs or T cells alone were infected with the same viral dose. RLU/s, relative light
units per second. Shown are averages values (±SD) derived from three infections.
(D–F) Dose-dependent inhibition of (D) primary HIV-1 isolates of different subtype and coreceptor usage (indicated in parentheses); (E) HIV-1 NL4-3
variants resistant to protease as well as nucleoside and non-nucleoside RT inhibitors (X11 and ZT3-1) and the fusion inhibitor T20 (DTV; L33S, I37Q/
V38M); and (F) HIV-1, HIV-2, and SIVmac and chimeric SIVmac239 clones containing HIV-1 89.6 and RN Env proteins. All curves give average values
obtained from triplicate infections.even at exceedingly high concentrations (Figure S1). HIV-1
NL4-3 replication in PBMCs was suppressed at 20 mM
and completely blocked at 100 mM (Figure 2B). Further ex-
periments confirmed that both isolated and chemically
synthesized VIRIP inhibit HIV-1 infection with the same
potency (data not shown). Binding of HIV-1 to DC-SIGN
on dendritic cells (DCs) in the periphery, and subsequent
transport and transmission to T cells in secondary lym-
phoid organs, may be important for the spread of HIV-1
in humans (Geijtenbeek et al., 2000). We found that VIRIP
blocked HIV-1 transmission by monocyte-derived DCs to
T cells at 100 mM (Figure 2C). Thus, even the presence of
an efficient virus attachment factor did not overcome the
ability of VIRIP to inhibit viral infection. We next examined
the effect of VIRIP on HIV-1 infection of P4-CCR5 indicator
cells (Charneau et al., 1994) expressing CD4 and both ma-
jor entry cofactors CXCR4 and CCR5. VIRIP inhibited pri-mary HIV-1 group B subtype A, B, C, D, F, and H strains
and several group O isolates with IC50 values ranging
from 4 to 20 mM (examples shown in Figure 2D). Thus,
the inhibitory activity of VIRIP was independent of viral
subtype or coreceptor usage. Notably, VIRIP also blocked
HIV-1 variants resistant to protease and RT inhibitors (X11,
ZT3-1) (Walter et al., 2000) and the fusion inhibitor T20
(DTV, L33S, I37Q/V38M) (Armand-Ugon et al., 2003; Rim-
sky et al., 1998; Figure 2E), suggesting that it may be ef-
fective in patients failing current HAART regimens. In com-
parison to all HIV-1 variants analyzed, the HIV-2 Rod,
SIVmac239, and SIVmac251 strains were hardly suscep-
tible to VIRIP inhibition (Figure 2F). However, infection by
SIV particles carrying HIV-1 Env proteins (SHIV-89.6 and
SHIV-RN) (Miyazaki et al., 2002; Reimann et al., 1996)
was blocked (Figure 2F). Thus, our data show that VIRIP
is a broad-spectrum inhibitor of HIV-1 Env function.Cell 129, 263–275, April 20, 2007 ª2007 Elsevier Inc. 265
Figure 3. Antiviral Effect of Full-Length a1-AT and VIRIP-Related Peptides
(A) C-terminal amino acid sequence of a1-AT and peptides analyzed. The protease cleavage site in the reactive center loop and the cleavage sites for
VIRIP are indicated by red and blue triangles, respectively. The four residues belonging to the reactive center of a1-AT are highlighted in yellow, the
asterisk indicates a stop codon, and the amino acids in the peptides differing from those found in a1-AT are underlined.
(B and C) Infection of P4-CCR5 cells with HIV-1 NL4-3 in the presence of (B) full-length a1-AT or (C) a variety of C-terminal fragments of a1-AT and
a scrambled form of VIRIP. A dotted line indicates 50% inhibition. None of the compounds showed cytotoxic effects at the concentrations used in the
inhibition studies. Shown are average values derived from triplicate infections.Specificity of VIRIP
To further evaluate the specificity of VIRIP, we tested the
antiviral effects of full-length a1-AT and several VIRIP-
related C-terminal fragments of a1-AT (Figure 3A). As ex-
pected from a previous study (Shapiro et al., 2001), a1-AT
also inhibited HIV-1 infection. However, the full-length
molecule was less potent than VIRIP, blocking HIV-1
infection by a maximum of 70%, whereas equimolar con-
centrations of VIRIP caused 99% inhibition (Figure 3B).
We found that after 24 to 48 hr incubation in human
plasma, about 50% of VIRIP was converted into an
N-terminally truncated derivative, (L-)VIRIP, lacking the
first leucine (data not shown). Surprisingly, this single
amino acid deletion resulted in a complete loss of antiviral
activity (Figure 3C). We also investigated the effect of sub-
stitutions of A355R and M358R (numbering corresponding
to the full-length a1-AT sequence). These alterations are
present in the a1-AT Portland variant, a high-affinity inhib-
itor of furin (Anderson et al., 1993), one of the proteases
cleaving the gp160 Env precursor (Hallenberger et al.,
1992). However, introduction of these changes into VIRIP
(PD-VIRIP) led to a decrease in its antiviral potency. Fur-
ther analysis confirmed that VIRIP does not inhibit serine
proteases (data not shown). In addition, the N- and C-ter-
minal moieties and a scrambled form of VIRIP (VIRscr)
were also inactive (Figure 3C). Thus, the 20-residue-266 Cell 129, 263–275, April 20, 2007 ª2007 Elsevier Inc.comprising VIRIP sequence blocks HIV-1 infection in a
highly specific manner.
Improved Antiviral Potency
To enhance the antiviral activity of VIRIP, we performed
a systematic structure-activity relationship (SAR) analysis.
At first, all possible positions in the original peptide were
replaced by L-alanine to determine critical residues. Anal-
ysis of these VIRIP derivatives revealed that the side
chains at the four N-terminal (LEAI) and the three C-termi-
nal (FVF) residues are crucial for antiviral activity, whereas
the remaining alterations were tolerated (Table S1). Nota-
bly, the K13A substitution resulted in a peptide with sig-
nificantly increased antiviral potency and reduced net
charge. Furthermore, we examined VIRIP derivatives
with an N-terminal acetyl group or with amidated C termi-
nus. The results demonstrated that the negative N-termi-
nal charge is crucial for antiviral activity (Table S1). In
addition, we found by testing peptides of a D-amino acid
scan that an epimer containing D-proline at position 10
also showed increased antiviral potency.
To carry out advanced SAR studies, further series of >600
VIRIP analogs were designed and chemically synthe-
sized, among them derivatives that contained a variety
of natural and non-natural amino acids at positions, which
tolerated substitution by alanine (examples shown in
Figure 4. Improved Antiviral Potency of VIRIP Derivatives
(A) P4-CCR5 indicator cells were infected with NL4-3 stocks containing 1.0 ng p24 antigen in the presence of VIRIP, a variety of VIRIP derivatives
(amino acid sequence shown in left panel; p, D-proline; cysteine residues are linked via a disulfide bridge), or T20. Average values obtained from quin-
tuple infections are shown (right panel). The results were confirmed in two to five independent experiments.
(B and C) Dose-dependent inhibition of (B) primary HIV-1 isolates of different subtype and coreceptor usage (indicated in parentheses) or (C) RT-,
protease-, and T20-resistant HIV-1 variants by VIR-576. NL4-3wt inhibition by VIRIP and T20 is shown for comparison. All curves give average values
obtained from triplicate infections. Similar results were obtained in two independent experiments.
(D and E) Inhibition of R5-tropic HIV-1 replication in ex vivo infected human tonsillary lymphocyte aggregate cultures by (D) VIR-353 and VIR-576 and
(E) T20. Shown are average luciferase activities in culture supernatants derived from triplicate infections. Similar results were obtained with another
R5-tropic HIV-1 clone and X4-tropic NL4-3wt. RLU/s, relative light units per second.Table S1). An additional approach to increasing antiviral
potency was the introduction of an intramolecular cyclic
motif by a disulfide bond. For this, residues were replaced
by cysteines to generate disulfide bonds. Such peptides
are considered to exhibit a more rigid structure with less
flexibility. Several of these VIRIP derivatives displayed
about two orders of magnitude increased anti-HIV-1 activ-
ity compared to the natural form (examples shown in
Figure 4A). Thus, some of them were equally potent as
T20 in blocking NL4-3wt infection (Figure 4A). The modi-fied forms of VIRIP were also highly active against diverse
primary HIV-1 strains and against RT-, protease-, and fu-
sion inhibitor-resistant virus variants (VIR-576 is shown
as an example in Figures 4B and 4C). Examination of the
infected cell cultures by electron microscopy confirmed
that VIR-576 protected the cells against cytopathic effects
and prevented virus production (Figure S2). Moreover,
VIRIP derivatives were highly effective in blocking trans
HIV-1 transmission from DCs to primary T cells
(Figure S3) and maintained significant antiviral activityCell 129, 263–275, April 20, 2007 ª2007 Elsevier Inc. 267
even after several days of incubation in human serum (VIR-
576 shown as an example in Figure S4). Thus, the antiviral
potency of VIRIP can be greatly improved by changing
specific amino acid side chains and/or particular structural
features such as charge and peptide chain rigidity.
To further assess the antiviral potency of VIRIP deriva-
tives we infected human lymphocyte aggregate cultures
(HLAC) of tonsils (Eckstein et al., 2001) with HIV-1 ex
vivo in the presence or absence of an inhibitor. Lymphoid
tissue is the site where most HIV-1 replication and the
critical events in the progression of AIDS occur in vivo
(reviewed in Stevenson, 2003). Thus, this ex vivo organ
culture system provides a relevant model for studying
the inhibitory effect of antiviral agents on HIV-1 replication
in humans. We found that VIR-353 and VIR-576 as inves-
tigated model analogs markedly inhibited the spread of
HIV-1 in ex vivo infected HLAC cultures at 100 nM and
completely blocked viral replication at 1 mM (Figure 4D).
In comparison, T20 suppressed HIV-1 replication at 5 mM
but not at 500 nM (Figure 4E). Thus, VIRIP derivatives
are potent inhibitors of HIV-1 replication in HLAC. Further
studies confirmed that VIRIP derivatives are active against
a wide variety of HIV-1 strains without causing cytotoxic
effects (Figure S1 and data not shown). In summary, our
findings show that VIRIP derivatives are highly promising
for further clinical development.
Inhibitory Mechanism of VIRIP
Our results showed that VIRIP blocks specifically the func-
tion of the HIV-1 Env protein (Figure 2A). In agreement with
these data, the original peptide inhibited HIV-1 Env-medi-
ated cell fusion with an IC50 of 26 mM (Figure 5A). Opti-
mized derivatives were about 100-fold more effective
than VIRIP, whereas (L-)VIRIP or VIRscr (Table S1) were in-
active. We next investigated which step of the HIV-1 entry
process is blocked. As shown in Figure S5, VIRIP and its
derivatives did not alter CD4 and CCR5 or CXCR4 core-
ceptor expression. In contrast to anti-CD4 antibodies
and the small molecule CCR5 inhibitor TAK-779, they
also did not affect binding of HIV-1 gp120 to CD4 or
CCR5 (Figure S6). Next, we examined whether VIRIP de-
rivatives inhibit six-helix bundle (6-HB) formation by the
gp41 N- and C-proximal heptad repeat (NHR and CHR, re-
spectively) regions, as do other HIV-1 fusion inhibitors
(Kilby et al., 1998; Root et al., 2001). This interaction can
be mimicked with synthetic N and C peptides correspond-
ing to the NHR and CHR regions, respectively, (Lu et al.,
1995) and detected by ELISA (Gallo et al., 2006; Jiang
et al., 1999) using a monoclonal antibody (NC-1) binding
specifically to the complex but not to the individual pep-
tides (Jiang et al., 1998). Unlike the fusion inhibitors
T1249 and C34 (Armand-Ugon et al., 2003; Eron et al.,
2004), none of the VIRIP derivatives inhibited 6-HB forma-
tion (Figure 5B). As expected from published data (Liu
et al., 2005), T20, which does not contain the cavity-bind-
ing domain (Chan et al., 1998), did not efficiently inhibit
6-HB formation of the fusogenic core.268 Cell 129, 263–275, April 20, 2007 ª2007 Elsevier Inc.Altogether, our results strongly suggested that VIRIP
does not affect CD4 binding, coreceptor interaction, or
formation of 6-HB. Thus, we next studied whether VIRIP
might interfere with the function of HIV-1 gp41 FP (FP1-
23). Incubation of human erythrocytes with synthetic
highly hydrophobic FP usually results in significant hemo-
lysis (Mobley et al., 1992). We found that the hemolytic ac-
tivity of FP1-23 was clearly inhibited by VIRIP but not by
(L-)VIRIP or VIRscr (Figure 5C). Notably, VIRIP derivatives
showing improved anti-HIV-1 activity (Figure 5D) were
also more potent in preventing HIV-1 gp41 FP-induced
hemolysis (Figures 5C and S7). Optimized VIRIP deriva-
tives also inhibited the hemolytic activity of the SIV/HIV-
2 FP, albeit only at higher concentrations. However, they
did not affect hemolysis induced by MLV FP (Figure 5C).
We found that T20 also displayed antihemolytic activity.
This was not surprising because T20 contains a high ratio
of hydrophobic residues and has been previously shown
to reduce HIV-1 gp41 FP-induced hemolysis (Mobley
et al., 2001). However, the effect on the HIV-1 and SIV/
HIV-2 FPs was weaker than that on the MLV FP (Fig-
ure 5C), although the latter virus is not susceptible to
T20 inhibition. These data suggest that T20 inhibits the
hemolytic activity of different FPs largely via nonspecific
hydrophobic interactions. In contrast, the antihemolytic
activity of VIRIP and its derivatives was highly specific
and correlated with their antiviral potency.
To assess whether alterations in the FP might affect the
sensitivity of HIV-1 to VIRIP inhibition, we replaced the FP
of NL4-3 with that of SIVmac239 (which is identical to
that of HIV-2). We found that significantly higher con-
centrations of VIRIP and its derivatives (average of 4.6 ±
1.4-fold; n = 8) were required for 50% inhibition of the FP
mutant compared to the parental HIV-1 clone (Figure 5D
and Table S2). In contrast, viral sensitivity to T20 inhibition
was 5.6-fold enhanced by exchanging the FP. We also ex-
amined SIVmac239 containing the HIV-1 FP but this chi-
mera was not infectious (data not shown). SIVmac239
was substantially less sensitive to VIRIP inhibition than
the HIV-1 chimera containing the SIV/HIV-2 FP, although
up to 70% inhibition of SIV was observed in the presence
of relatively high concentrations of optimized VIRIP deriv-
atives (Figures 5C and S8). Taken together, the results of
the hemolysis and inhibitions studies show that VIRIP de-
rivatives interact strongly with the HIV-1 FP, less efficiently
with the SIV/HIV-2 FP, and not at all with the MLV FP. How-
ever, possibly due to altered fusion kinetics and/or acces-
sibility of the FP, the viral envelope backbone also affects
the susceptibility of HIV-1 to VIRIP inhibition.
Structure of the Complex between VIR-165
and the gp41 FP
To further elucidate the inhibitory mechanism we analyzed
the binding specificity of the optimized VIR-165 derivative
(Figure 4A) with gp41 FP1-23 by NMR spectroscopy. To
facilitate the NMR assignments the measurements were
performed at pH 4.7, which is lower than under physiolog-
ical conditions (pH 7.2). The fact that the two peptides are
Figure 5. Inhibitory Mechanism of VIRIP
(A) Inhibition of HIV-1 Env-mediated cell fusion by the indicated peptides. Identical symbols are also used in (B)–(D). Average values of triplicate mea-
surements are shown in (A)–(C).
(B) Inhibitory effect of VIRIP derivatives and fusion inhibitors on gp41 6-HB formation.
(C) Inhibitory effect of VIRIP derivatives and T20 on hemolysis induced by HIV-1, SIV/HIV-2, and MLV FPs.
(D) Inhibition of NL4-3wt, an NL4-3 chimera containing the SIV/HIV-2 FP and SIVmac239, by various VIRIP derivatives and T20. The upper panel
shows an alignment of the gp41 FP sequences of HIV-1 and SIV/HIV-2. Dashes and the dot indicate amino acid identity and a gap, respectively.
Average values obtained from sextuple infections of P4-CCR5 indicator cells are shown.interacting was confirmed by NMR spectroscopy using
nuclear Overhauser and exchange spectroscopy (NOESY)
spectra at 250 MHz. At this frequency the NOEs of the free
peptides are still positive, indicative of the monomeric na-
ture of the peptides. However, the NOESY spectrum of
a mixture of the two peptides at 250 MHz shows negative
signs of the NOEs proving the formation of a heterodimeric
complex in solution.To quantify the interaction of VIRIP derivatives with the
gp41 FP we performed Biacore studies. Results obtained
using immobilized HIV-1 gp41 FP and prototype VIRIP
derivatives showed that VIR-165 binds about 20-fold
more strongly to FP1-23 than (L-)VIRIP (data not shown).
This leads to a 60-fold faster association as evident from
the association rates (kon) of VIR-165 (kon = 3.2 3 10
5
M1s1) and (L-)VIRIP (kon = 5.4 3 10
3 M1s1). TheseCell 129, 263–275, April 20, 2007 ª2007 Elsevier Inc. 269
data suggest that (L-)VIRIP is not assuming a structure as
well defined as that of VIR-165, indicating that the first leu-
cine in VIRIP is critical for antiviral activity because it sta-
bilizes the secondary structure of the N-terminal section.
The analysis of the binding kinetics from VIR-576 yielded
kon = 4.5 3 10
5 M1s1, whereas VIRscr showed no spe-
cific binding. Thus, only the two inhibitory prototype VIRIP
derivates but not the inactive control peptides associated
efficiently with the HIV-1 gp41 FP.
Combination of NMR data obtained at 700 MHz and at
500 MHz proved to be beneficial for the complete assign-
ment of all NH and CHa resonances of FP1-23 and VIR-
165 (summarized in Tables S3 and S4). An almost com-
plete assignment of side-chain protons was possible.
The conformation of the individual peptides was obtained
from NOESY spectra in buffered solution. Long-range in-
teractions with the associated distances are listed in Table
S5. The structure of the complex of FP1-23 and VIR-165
was further analyzed by NOESY experiments applied to
an equimolar mixture of the two peptides (not shown). Un-
fortunately, it was difficult to unambiguously assign many
of the intermolecular NOESY crosspeaks even at 700 MHz
since the chemical shifts of the protons of the two pep-
tides are very similar, thus resulting in a considerable over-
lap of the signals obtained in the NOESY spectra of the
mixture. On the basis of the NH, CHa, and side-chain as-
signments, key intermolecular NOE crosspeaks were
identified (Table S6). Importantly, these show the close
proximity of the newly introduced residue F12 of VIR-
165 to L12 of FP1-23.
Using unambiguous key intermolecular NOEs between
the two peptides in the complex, it was possible to con-
struct a docking model of FP1-23 and VIR-165. The con-
formation of the two peptides was initially kept the same
as determined in solution. Applying the key intermolecular
NOEs the DYANA distance geometry simulation yielded
a complex in which both peptides basically remained in
the respective structure that they had each adopted sep-
arately in the solution. This model was then used as a start-
ing model for a refinement procedure utilizing an MD sim-
ulation with the TRIPOS force field. During this 500 ps
simulation all NOE restraints, including intermolecular
ones, were active and yielded a final refined structure of
the complex of FP1-23 and VIR-165. The resulting model
is in excellent agreement with the experimental con-
straints as seen in Table S6. Our data also show that the
two peptides already adopt their bioactive conformation
before the complex is formed. Large highly complemen-
tary hydrophobic surfaces are responsible for the strong
and remarkably specific interaction between VIR-165
and the gp41 FP (Figure 6). The model also explains the
enhanced antiviral activity of VIR-165 as compared to
VIRIP. The mutated amino acids in VIR-165, i.e., F12
and A13, have close proximity to and make hydrophobic
contact to residues of FP1-23. The two newly introduced
cysteine residues stabilize the active conformation of
VIR-165, which is necessary for its tight interaction with
FP1-23.270 Cell 129, 263–275, April 20, 2007 ª2007 Elsevier Inc.The HIV-1 gp41 FP Is a Useful Drug Target
To select resistant variants we initially performed serial
passages of NL4-3 or mixtures of molecular HIV-1 clones
in PBMCs in the presence of VIRIP, T20, or T1249, respec-
tively. We found that no VIRIP- or T1249-resistant forms of
HIV-1 emerged within two months of weekly passage. On
the other hand, as expected based on previous studies
(Rimsky et al., 1998), T20-resistant HIV-1 isolates contain-
ing changes in the ‘‘GIV’’ motif of the gp41 HR1 region
emerged after 3 to 4 passages (data not shown). To clarify
Figure 6. Structure of the VIRIP-FP Complex
(A–C) The complex of the two peptides: left VIR-165 (red and light
green), right FP1-23 (blue and magenta). The amino acids interacting
with each other are shown in light green and blue, respectively. The
N-terminal amino acid of VIR-165, i.e., leucine, is shown in green. (A)
The peptides FP1-23 and VIR-165 as ribbon and stick models; (B) pep-
tide FP1-23 as surface plot and the inhibitor VIR-165 as stick model
(hydrogen atoms not shown); (C) the two peptides VIR-165 and FP1-23
shown as surface plots. The complementarity of the surfaces is
self-evident.
Figure 7. Mutational Analysis of the HIV-1 gp41 FP Region
(A) Infectivity of HIV-1 NL4-3 gp41 variants containing randomized codons in the HR1 region. The positions of the randomized residues in the FP
region are indicated. Viral infectivity was measured by infection of TZM-bl cells with virus stocks containing normalized amounts (10 ng) of p24
core antigen and represents average values ±SD derived from triplicate infections. The numbers after the infectivity bars indicate n-fold reduction
of infectivity compared to NL4-3wt virus. Similar results were obtained in three independent experiments and with CEM-M7 indicator cells. Controls
are shown in green, FP mutants displaying >100-fold reduced infectivity compared to NL4-3wt in red, and those showing <100-fold reduction in
infectivity in blue.
(B and C) Inhibition of HIV-1 mutants containing random changes in the (B) gp41 FP region or (C) in the ‘‘GIV’’ motif by VIR-576 and T20, respectively.
NL4-3wt inhibition is shown for comparison. The infectivity of the remaining FP variants and of the two HIV-1 mutants containing changes in the deep
cavity region was too low for meaningful analysis. All curves give average values ±SD obtained from triplicate infections.why it might be difficult to select VIRIP-resistant virus var-
iants, we generated a set of 15 HIV-1 mutants, containing
random changes in the gp41 FP region (Figure 7A). As
controls, we randomized residues in or near the ‘‘GIV’’ mo-
tif (known to play a key role in T20 resistance; reviewed in
Greenberg and Cammack, 2004) and in the deep hydro-
phobic cavity (known to be highly conserved and to repre-
sent a good drug target; Chan et al., 1998) of the NL4-3
gp41 HR1 region. All proviral plasmid preparations repre-
sented a large number of independent transformants
(984± 361; average±SD, n = 19) and contained a complex
mixture of nucleotide changes in the targeted codons (Fig-
ure S9 and data not shown). HIV-1 mutants containing
random changes in the FP or deep cavity regions usually
showed grossly impaired infectivity, whereas changes in
the ‘‘GIV’’ motif were better tolerated (Figure 7A). We
found that none of the FP mutant virus stocks displayed
significantly reduced sensitivity to VIR-576 (Figure 7B).
In contrast, the two HIV-1 pools containing changes in
the gp41 ‘‘GIV’’ motif were resistant to T20 but not to
VIR-576 (Figure 7C). No resistant virus variants were de-
tected after propagation of the 15 HIV-1 mutants contain-
ing random changes in the gp41 FP region in CEM-M7cells in the presence of VIR-576, whereas analogous ex-
periments allowed the effective selection of T20-resistant
forms (data not shown). These results show that changes
in the gp41 FP region usually either are not tolerated or do
not confer resistance to VIR-576, which likely explains
the difficulty to generate VIRIP-resistant HIV-1 variants
in vitro.
DISCUSSION
An Inhibitor Targeting the HIV-1 gp41 FP
This study demonstrates that a 20-residue C-proximal
fragment of a1-AT is a potent broad-spectrum inhibitor
of HIV-1 since VIRIP blocks infection by all HIV-1 variants
tested, regardless of their subtype or coreceptor usage.
VIRIP specifically inhibits HIV-1 Env function and hardly,
or not at all, affects infection by virions containing HIV-2,
SIV, MLV, or VSV Env proteins or by other human patho-
gens such as Ebola, Herpes Simplex, or Respiratory Syn-
cytial Virus (data not shown). To date the most advanced
HIV-1 entry inhibitors target CD4 binding, coreceptor in-
teraction, or gp41-mediated membrane fusion (reviewed
in Jiang et al., 2002; Moore and Stevenson, 2000; RayCell 129, 263–275, April 20, 2007 ª2007 Elsevier Inc. 271
and Doms, 2006). In contrast, VIRIP and its derivatives
seem to act by a distinct mechanism. Our functional and
structural data consistently indicate that VIRIP derivatives
inhibit HIV-1 entry by binding to the gp41 FP and prevent-
ing its insertion into the target cell membrane. In agree-
ment with our experimental results (Figures 2E and 4C),
this property implies that VIRIP derivatives are active
against HIV-1 variants that are resistant to other entry
inhibitors making them highly suitable for further clinical
development.
The significantly reduced susceptibility of the HIV-1 chi-
mera containing the SIV/HIV-2 FP (Figure 5D and Table
S2) shows that mutations in the gp41 FP region can confer
partial resistance to VIRIP inhibition. We found, however,
that it is difficult to select VIRIP-resistant HIV-1 variants
in vitro. This is not entirely unexpected because the
gp41 FP region is highly conserved, and it has also proven
challenging to obtain HIV-1 mutants resistant against 2nd
generation fusion inhibitors (reviewed in Ray and Doms,
2006). Our results show that most changes in the gp41
FP region are usually not tolerated or do not confer resis-
tance to an optimized VIRIP derivative (Figure 7). More-
over, a combination of changes (seven in the case of the
chimeric virus) seems required for significant resistance.
Altogether, these results explain the difficulty to select
VIRIP-resistant HIV-1 variants in cell culture. The FP hy-
brid virus shows enhanced susceptibility to T20 inhibition
(Table S2). The reason for this remains elusive, but obvi-
ously decelerated fusion kinetics of the chimeric gp41
could be responsible for this phenotype and may also
explain why the HIV-1 SIV-FP chimera is more susceptible
to inhibition by VIRIP derivatives than SIVmac239
(Figure 5D).
It has been previously shown that full-length a1-AT also
affects HIV-1 replication (Shapiro et al., 2001). We con-
firmed these findings but also found, however, that VIRIP
inhibits HIV-1 with higher efficacy than full-length a1-AT.
Our data also imply that the modes of action are different.
VIRIP does not affect HIV-1 promoter activity and, unlike
a1-AT, does not inhibit HIV-2 Rod infection. VIRIP exhibits
no significant inhibitory effect on a number of serine pro-
teinases, including human neutrophil elastase, trypsin,
thrombin, and tryptase and does not affect cleavage of
the gp160 Env precursor into gp120 and gp41 (data not
shown). Thus, our data demonstrate that VIRIP acts via
a different mechanism and is a more potent inhibitor of
HIV-1 than full-length a1-AT.
Possible Role of VIRIP in HIV-1-Infected Individuals
VIRIP was isolated from a complex peptide library repre-
senting essentially all low-molecular-weight compounds
circulating in human blood (Forssmann et al., 1992). Frac-
tion P1-20 was more potent in inhibiting HIV-1 than all
remaining HF-derived peptide fractions, suggesting a rele-
vant role of the inhibitory compound in vivo. The anti-HIV-
1 potency of the original fraction indicates that the plasma
concentration of VIRIP is about 1 mM (Figure 1A). Exact
quantification of VIRIP in human plasma proved to be272 Cell 129, 263–275, April 20, 2007 ª2007 Elsevier Inc.complicated because quantitative separation from full-
length a1-AT and other inactive C-terminal subfragments
was difficult to achieve. It should be noted, however, that
a1-AT is the most abundant circulating serpin reaching
plasma concentrations up to 250 mM during acute infec-
tion or inflammation (reviewed in Brantly et al., 1988;
Kushner, 1988). Under these conditions less than 5% of
the precursor molecule needs to be converted to VIRIP
to reach the in vitro IC50. We, as well as others, found
that matrix metallo-proteinases (MMPs) 2 and 9 generate
the N terminus (F352YL353) of VIRIP (Desrochers and
Weiss, 1988) (data not shown). Most likely, related prote-
ases cleave at the C terminus of VIRIP containing the
same amino acid motif (F372YL373). MMPs are elevated
in response to inflammation or HIV infection (Goetzl
et al., 1996; Johnston et al., 2000). Accordingly, HIV-1 in-
fection presumably induces both, the a1-AT precursor
and the proteases involved in the generation of VIRIP. In
summary, our results indicate that VIRIP might impact dis-
ease progression in HIV-1-infected individuals.
Complex between the HIV-1 gp41 FP
and an Improved VIRIP Derivative
A complete sequential assignment of the peptides was
achieved using 700 MHz NMR experiments. Long-range
NOEs allowed us to elucidate the solution structures of
FP1-23 and VIR-165. The analysis of the mixture of the
peptides utilizing NOESY experiments revealed that
FP1-23 and VIR-165 associate mainly via hydrophobic in-
teractions of the amino acid side chains. A model of the
structure generated using distance geometry (DYANA)
and molecular dynamics calculations shows clearly that
the high specificity of the recognition of FP1-23 by VIR-
165 is due to remarkably complementary surfaces of the
two peptides (Figure 6). The model also explains the en-
hanced specificity and affinity of VIR-165 compared to
the parent VIRIP and the results of our comprehensive
SAR analysis of >600 VIRIP analogs. Additional hydropho-
bic amino acids in VIR-165 or other optimized VIRIP deriv-
atives increase the hydrophobic contact area between the
two complementary surfaces. In contrast, changes in the
C-terminal (FVF) residues of VIRIP disrupt antiviral activity
(Table S1) because they eliminate critical hydrophobic in-
teractions with residues in the gp41 FP (Figure 6). Our re-
sults further indicate that a disulfide bridge stabilizes and
elimination of the first leucine destabilizes the active con-
formation of VIRIP required for effective gp41 FP binding
and hence antiviral activity. The solution structure of the
FP1-23/VIR-165 complex not only explains the antiviral
activity of VIRIP and its derivatives but also provides a ba-
sis for a rational approach to design even more potent
inhibitors.
Perspectives
VIRIP exhibits interesting properties for further therapeu-
tics/drug development. It is active against a broad variety
of HIV-1 variants and targets the highly conserved gp41
FP. Our studies show that the gp41 FP region is an
attractive drug target and demonstrate that it is difficult to
obtain VIRIP-resistant HIV-1 variants, at least in cell cul-
ture. Furthermore, we found that many VIRIP derivatives
are highly stable in human plasma and not cytotoxic
even at exceedingly high concentrations. For selected
VIRIP derivatives the lack of toxicity has also been con-
firmed in animal models. Importantly, a few amino acid
changes enhance the antiviral potency of VIRIP by about
two orders of magnitude. Thus, further development of
VIRIP as an antiviral agent may lead to a new class of entry
inhibitors expected to block HIV-1 variants resistant to
currently available antiretroviral agents.
EXPERIMENTAL PROCEDURES
Identification of VIRIP
Peptides were extracted from 10,000 liters of human HF derived from
patients with chronic renal disease and fractionated by cation-
exchange (pH pool fractions 1–7). Subsequently, RP chromatography
was performed, where 46 fractions per pool were obtained, as re-
ported (Forssmann et al., 1992). The resulting 322 fractions were
tested for their ability to block HIV-1 NL4-3 replication in PBMCs as
described (Detheux et al., 2000). Fraction P1-20 displaying strong
anti-HIV-1 activity was further separated by two additional RP-HPLC
steps, and biochemical characterization of the purified peptide was
performed as documented (Mark et al., 1999).
Peptide Synthesis
All peptides were prepared by Fmoc solid-phase synthesis as
described (Fields and Noble, 1990) and subsequently purified by
reversed-phase chromatography. Identity and homogeneity of the
products were analyzed by reversed-phase HPLC, capillary zone elec-
trophoresis, electrospray MS, and sequence analysis.
HIV-1 Variants and Virus Stocks
Primary HIV-1 isolates and HIV-2 Rod were obtained through the NIH
AIDS Reagent Program. Molecular clones and the generation of virus
stocks are described in the Supplemental Experimental Procedures.
HIV-1 Infectivity, Replication, and Transmission
The inhibitory effect of the peptides on viral replication in PBMCs and
on infectivity in P4-CCR5 cells was assayed as described previously
(Detheux et al., 2000; Mu¨nch et al., 2002). Inhibition of PBMC infection
was measured by infection with NL4-3 variants containing the lucifer-
ase gene in place of nef as described (Hiebenthal-Millow and Kirchhoff,
2002). Immature DCs were generated as described (Prechtel et al.,
2005). A luciferase encoding NL4-3-based reporter virus was added
to 5000 immature DCs in a total volume of 140 ml. After 2 hr unbound
virus was removed and cells were resuspended in 100 ml RPMI.
Then, 20 ml of the various VIRIP dilutions or (L-)VIRIP (1000 mM) and
5000 PHA/IL-2-stimulated PBMC containing autologous serum
(80 ml) were added to the DC cultures. As control DCs were treated
with Mannan (500 mg/ml) prior to infection. Luciferase activities were
detected at 3 days post-infection.
Human Tonsillary Lymphocyte Aggregate Cultures
Human lymphoid tissues were processed and cultured as described
(Eckstein et al., 2001). Infections are described in the Supplemental
Experimental Procedures.
Gp41 Six-Helix Bundle Formation
The conformation-specific mAb NC-1 (Jiang et al., 1998) was used in
a modified ELISA as previously described (Gallo et al., 2006) to deter-
mine the effect of VIRIP and its derivatives on the gp41 6-HB formationbetween N36 and biotinylated C34 (C34-biotin). For details, see the
Supplemental Experimental Procedures.
HIV-1-Mediated Cell Fusion
A dye transfer assay was used for detection of HIV-1-mediated cell fu-
sion as described (Jiang et al., 2000). For details, see the Supplemental
Experimental Procedures.
Hemolysis
Hemolysis was determined as described (Helmerhorst et al., 1999). For
details, see the Supplemental Experimental Procedures.
Structural Analysis
The methods used to determine the solution structures of the FP1-23
and VIR-165 peptides and of the complex are described in the Supple-
mental Experimental Procedures.
Biacore Analysis
Surface plasmon resonance studies are described in the Supplemen-
tal Experimental Procedures.
HIV-1 gp41 FP Random Mutants
Site-specific random mutagenesis of the HIV-1 NL4-3 molecular clone
was performed by splice-overlap extension PCR using wobble
primers. For details, see the Supplemental Experimental Procedures.
Statistical Analysis
IC50 values were compared using a two-tailed Student’s t test. The
PRISM package version 4.0 (Abacus Concepts, Berkeley, CA) was
used for all calculations.
Supplemental Data
Supplemental data include Experimental Procedures, nine figures, and
six tables and can be found with this article online at http://www.cell.
com/cgi/content/full/129/2/263/DC1/.
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